2021
DOI: 10.3892/ol.2021.12719
|View full text |Cite
|
Sign up to set email alerts
|

Inhibition of aquaporins as a potential adjunct to breast cancer cryotherapy

Abstract: Cryoablation is an emerging type of treatment for cancer. The sensitization of tumors using cryosensitizing agents prior to treatment enhances ablation efficiency and may improve clinical outcomes. Water efflux, which is regulated by aquaporin channels, contributes to cancer cell damage achieved through cryoablation. An increase in aquaporin (AQP) 3 is cryoprotective, whereas its inhibition augments cryodamage. The present study aimed to investigate aquaporin (AQP1, AQP3 and AQP5) gene expression and cellular … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 66 publications
0
6
0
Order By: Relevance
“…In view of this, inhibition of aquaporins have been suggested to be beneficial. 29 , 30 Therefore, activation of noncanonical Wnt signaling and Aquaporin 7 are some of the important future areas of research in breast cancer.…”
Section: Discussionmentioning
confidence: 99%
“…In view of this, inhibition of aquaporins have been suggested to be beneficial. 29 , 30 Therefore, activation of noncanonical Wnt signaling and Aquaporin 7 are some of the important future areas of research in breast cancer.…”
Section: Discussionmentioning
confidence: 99%
“…AQP3 participates in the plasma membrane permeability and intracellular water retention, which increases the critical freezing temperature to maintain cell survival advantage with cryoablation treatment. AQP inhibitors (mercuric chloride) combinate with cryoablation significantly reverses resistance and improve treatment effects ( 109 , 110 ), which supported AQP inhibitors in combination with cryoablation-immunotherapy in clinical practice. Combined cryoablation with Toripalimab (anti-PD-1) and Lenvatinib (anti-angiogenic agent) in a metastatic HCC patient also achieved CR at 7 months after treatment, and PFS as 24 months ( 111 ).…”
Section: Challenges For Combining Ablation and Immunotherapymentioning
confidence: 88%
“…Whether the formation of intracellular ice crystals or dehydration that dominates cellular death is still elusive. Regardless, membrane fluidity and permeability are crucial to cell viability during the freeze-thaw process 199 . More fluid cells tend to survive due to flexibility in the membranes as they swell or shrink under osmotic pressure.…”
Section: Nanomaterials In Cryoablation: a New Opportunitymentioning
confidence: 99%
“…However, as aquaporins exist in normal cells as well, nanoparticle-based delivery system of aquaporin inhibitors can be used to reduce the chance of side effects and synergize with cryoablation. Inhibition of aquaporins in cultured prostate and breast cancer cells enhanced cryoinjury 199 , 200 .…”
Section: Nanomaterials In Cryoablation: a New Opportunitymentioning
confidence: 99%